Enhanced 3D vision
Improved detail, colour and depth perception support the surgeon’s view of the tissues.
Sources checked • October 2026
Medical technologies & developments: 2026
Understand technology names and questions to discuss with your clinician. Official sources were checked on 2 October 2026. A device name or approval in one country does not establish availability for every case or hospital.
Sources last reviewed: 2 October 2026 · Blue Crescent
On this page
New: da Vinci 5 technology
da Vinci 5: the next generation of robotic-assisted surgery
An Intuitive surgical system that helps a surgeon perform selected operations through small incisions. The surgeon controls the instruments from a console throughout the operation; the robot does not operate on its own.
What is new, and how can it help?
Force Feedback
Compatible instruments convey push and pull sensations to help the surgeon judge tissue interaction.
Surgeon comfort and control
A more adjustable console integrates operating-room functions, with tools for training and performance review.
How does it differ from da Vinci Xi?
da Vinci 5 is a different generation from Xi, with changes to vision and the console and Force Feedback on compatible instruments. A hospital with Xi does not necessarily have 5. The generation name alone does not establish a better result for your case.
Which procedures may be considered?
A specialist may consider selected urological, general, gynaecological and thoracic operations. Actual use depends on local authorisation, branch equipment, surgeon experience and individual assessment.
Potential benefits and an individual decision
The aim is to support minimally invasive surgery and instrument control. These features do not guarantee less pain, earlier discharge or better cancer outcomes. Published Force Feedback evidence includes preclinical studies; it does not establish a particular reduction in patient complications. Bleeding, infection, tissue injury and anaesthetic risks remain possible.
Ask your specialist before deciding
- Is da Vinci 5 suitable for my diagnosis, and what are the alternatives?
- What experience does the surgeon have with this procedure and system?
- What are the risks, written cost estimate and expected follow-up?
Advanced technology. Individual decisions.
These examples are grounded in official sources. A technology is not suitable for everyone or available at every branch; we confirm the centre, clinician and eligibility before coordination.
New: da Vinci 5 technology
Enhanced 3D vision and Force Feedback with compatible instruments, controlled by the surgeon. Explore potential benefits, limitations and availability.
Read the explanation and benefitsRobot-assisted surgery
Surgeon-controlled systems; Artemis describes Da Vinci Xi. Suitability is discussed after individual assessment.
SourceFocused radiosurgery
Radiation technology for selected tumours, described by Medanta. Its name does not imply a scalpel or surgical incision.
SourceBrain-focused radiosurgery
Apollo Delhi describes ZAP-X for focused radiation in selected brain tumours and neurological conditions.
SourceImmune cell therapy
IIT Bombay confirms Indian approval of NexCAR19 for relapsed or refractory B-cell lymphomas and leukaemia.
SourceCatheter-based valve replacement
Medanta describes catheter-based aortic valve replacement for selected severe aortic stenosis cases, assessed by the cardiac team.
SourceCancer biomarker testing
Gene and protein tests can inform treatment options, according to the US National Cancer Institute.
SourceRobotic joint surgery
BLK-Max announces robotic joint replacement systems. The orthopedic assessment determines the procedure and system.
SourcePrecision radiation systems
Max describes TrueBeam and stereotactic radiotherapy. The appropriate system and branch are confirmed before coordination.
SourceVerified global developments in 2026
The following updates concern US FDA decisions. They are informational; availability and approval in India, and patient eligibility, require separate confirmation from the treating centre.
Expanded cellular therapy indication
On 17 June 2026, FDA expanded TECELRA to patients aged 12 and older with specified previously treated synovial sarcoma and HLA/MAGE-A4 criteria.
SourceApproval for a kidney cancer combination
On 24 September 2026, FDA approved belzutifan with lenvatinib for adults with advanced clear-cell-component renal cell carcinoma after a PD-1 or PD-L1 inhibitor.
SourceQuestions to take to your specialist
What is the treatment goal in my case? Why this technology and what are the alternatives? What risks should I understand? Which tests are required? What stay and follow-up are expected? What does the quote cover? Ask for case-specific written answers rather than a general success percentage.
Frequently Asked Questions About 2026 Medical Technologies in India
Are Da Vinci, CyberKnife, ZAP-X and CAR-T available at partner hospitals?
Yes, these technologies are published by partner hospitals in Delhi and Gurgaon (such as Medanta, Apollo, Artemis, Fortis and BLK-Max). Suitability is confirmed by the specialist after reviewing your reports.
Do Blue Crescent discounts apply to advanced surgical procedures?
Yes, our hospital contracts provide 10% off surgical operation costs, 50% off prescribed oncology medicines, and 20% off general medicines, with free coordination and translation.
Treatment updates
Understand what changed in treatment and distinguish regulatory approval from experimental research before planning travel.
Explore verified updates